✦ LIBER ✦

A phase II study of LY355703 (cryptophycine) as first-line therapy for stage IIIb or IV NSCLC subjects: preliminary analysis

✍ Scribed by G. Groth; K. Schott; U. Ohnmacht; C. Manegold; U. Gatzemeier

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

9142 A phase II study of gefitinib monot

✍ Takahashi, K.; Saito, H.; Hasegawa, Y.; Ogasawara, T.; Taniguchi, H.; Suzuki, R. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

A phase II trial of pemetrexed and gemci

✍ Blakely, L. Johnetta; Schwartzberg, Lee; Keaton, Mark; Schnell, Fred; Henry, Dav 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 175 KB

9147 Bevacizumab and erlotinib as first-

✍ Zappa, F.; Droege, C.; Betticher, D.; von Moos, R.; Ochsenbein, A.; Stahel, R.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Capecitabine in combination with oxalipl

✍ Twelves, C.; Butts, C.; Cassidy, J.; Conroy, Th.; DeBraud, F.; Díaz-Rubio, E.; F 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 170 KB

P-463 Preliminary results of a multicent

✍ Bernardini, I.; Rinaldi, M.; Crinò, L.; Nardi, M.; De Marinis, F.; Tonato, M.; S 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 130 KB